DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.13
+0.33 (+3.37%)
At close: 4:00PM EST

10.13 0.00 (0.00%)
After hours: 4:42PM EST

Stock chart is not supported by your current browser
Previous Close9.80
Open9.74
Bid9.13 x 4000
Ask10.10 x 800
Day's Range9.55 - 10.23
52 Week Range6.98 - 31.42
Volume340,900
Avg. Volume497,563
Market Cap426.685M
Beta (3Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-4.91
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold DERM had net inflows of $1.14 billion over the last one-month.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of DERM earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Dermira Inc Earnings Call

  • GlobeNewswire7 days ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Nov. 08, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates
    Zacks8 days ago

    Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire8 days ago

    Dermira Reports Third Quarter 2018 Financial Results

    Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to.

  • GlobeNewswire15 days ago

    Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018

    MENLO PARK, Calif., Oct. 31, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire23 days ago

    Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the completion of patient enrollment in the Phase 2b dose-ranging study evaluating its anti-IL13 monoclonal antibody, lebrikizumab, in patients with moderate-to-severe atopic dermatitis. The company expects to announce topline efficacy and safety results from the study by early April 2019. “For many living with moderate-to-severe atopic dermatitis, the condition can often be debilitating, with patients finding limited treatment options that are effective at addressing the underlying cause of the disease,” said Luis Peña, chief development officer of Dermira.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit23 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.77 billion over the last one-month into ETFs that hold DERM are not among the highest of the last year and have been slowing.

  • GlobeNewswire29 days ago

    Report: Exploring Fundamental Drivers Behind Dermira, California Resources, OGE Energy, Oasis Petroleum, Harmonic, and CBIZ — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on October 8, 2018, the company granted inducement awards to nine new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 8,250 shares of Dermira common stock and stock options to purchase an aggregate of 44,825 shares of Dermira common stock.

  • GlobeNewswirelast month

    Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced its collaboration with Council of Fashion Designers of America, Inc. (CFDA) fashion designer Christian Siriano for the Check Your Sweat educational campaign. Check Your Sweat is designed to raise awareness of excessive underarm sweating, or primary axillary hyperhidrosis, a treatable medical condition.

  • GlobeNewswirelast month

    Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today that QBREXZA™ (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $5.36 billion.

  • GlobeNewswire2 months ago

    Dermira to Present at Cantor 2018 Global Healthcare Conference

    MENLO PARK, Calif., Sept. 25, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...

  • GlobeNewswire2 months ago

    Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today presented data from a post-hoc analysis of the Phase 3 open-label ARIDO study which evaluated the long-term safety of glycopyrronium tosylate in patients with primary axillary hyperhidrosis. The data showed the response of pediatric patients (ages 9 to 16) compared to older patients (ages 17 years and older) with primary axillary hyperhidrosis who received treatment with glycopyrronium tosylate (now QBREXZA™ (glycopyrronium) cloth).

  • GlobeNewswire2 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on September 7, 2018, the company granted inducement awards to 116 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 35,550 shares of Dermira common stock and stock options to purchase an aggregate of 77,775 shares of Dermira common stock.

  • GlobeNewswire2 months ago

    Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced several updates related to the upcoming launch and availability of QBREXZA™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis, also known as excessive underarm sweating, is a chronic medical skin condition that results in sweating beyond what is needed for normal body temperature regulation. “QBREXZA is the culmination of more than 10 years of clinical development work,” said Tom Wiggans, chairman and chief executive officer of Dermira.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold DERM had net inflows of $499 million over the last one-month.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $1.01 billion.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, ...

  • Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of 0.00% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Dermira: 2Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 57 cents per share. The skin condition drug developer posted revenue of $39.1 million in the period. Dermira shares have fallen 64 percent ...